Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hamburg Edoxaban for anticoagulation in COVID-19 (HERACLES)
2020-002504-39Phase 3Terminated
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of edoxaban in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Composite morbidity and mortality endpoints. Started Aug 2020; status: terminated.
02
Drugs
edoxaban
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-002504-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002504-39.